Navigation Links
Thoratec Announces Filing of PMA Seeking Destination Therapy Approval for HeartMate II(R)
Date:4/20/2009

PLEASANTON, Calif., April 20 /PRNewswire-FirstCall/ -- Thoratec Corporation (Nasdaq: THOR), a world leader in device-based mechanical circulatory support therapies to save, support and restore failing hearts, said today that it has filed a PMA (Pre-Market Approval) supplement with the FDA seeking to add the intended use of Destination Therapy (DT) for the HeartMate II LVAS (left ventricular assist system). The HeartMate II is a next generation heart assist device designed to provide long-term cardiac support for patients suffering from advanced stage heart failure. The device was approved for Bridge-to-Transplantation (BTT) in the U.S. under the original PMA in April 2008.

The PMA filing includes data on a pivotal study cohort of 200 randomized patients, including two-year data on the first 167 patients enrolled. Also included in the primary analysis are data on 24 small BSA (body surface area) patients who because of their body size could not be randomized to the larger HeartMate XVE. The filing also provides data on adjunctive cohorts totaling an additional 409 patients, including those who had been originally supported by an XVE who then elected to receive a HeartMate II, based on the need for device replacement, and patients enrolled under Continuous Access Protocols (CAPs). The company plans to file an amendment to the PMA supplement submission with complete two-year data on all 200 randomized patients at the end of June.

"We are pursuing this approach and making this submission at this time based on a series of discussions with the FDA. An interim analysis conducted at the end of 2008 for the primary endpoint demonstrated statistically significant superiority in favor of the HeartMate II versus the control group. As a result, Thoratec and the FDA have agreed that it is appropriate to make this filing now and to then file
'/>"/>

SOURCE Thoratec Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Thoratec Announces HeartMate II(R) PMA Will be Reviewed by FDA Advisory Panel
2. Thoratec Presentation at Bear Stearns Conference To Be Webcast
3. Thoratec Announces Appointment of Steven H. Collis to Board of Directors
4. Thoratec Presentation at JP Morgan Conference to be Webcast
5. Thoratec Reports 10 Percent Increase in Fiscal 2007 Revenues; Fourth Quarter Revenues Largest in Company History
6. Thoratec Schedules Third Quarter 2008 Conference Call, Webcast
7. Thoratec Reports 44 Percent Increase in Third Quarter Revenues
8. Thoratec Presentation at J.P. Morgan Conference to be Webcast
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
11. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... the right people at the table for significant business ... achieving clinical and operational goals. The 22 nd ... 2014, in San Diego , featured ... discussing how partnerships have positively impacted their objectives. ... Officer of Cape Regional Medical Center located in ...
(Date:7/23/2014)... , July 23, 2014 ... portfolio company of Trendlines Agtech , announced ... Israel,s leading agricultural thermoplastics ... Valentis,s technology combines nanocrystalline cellulose (NCC), ... waste, with additional nanoparticles to produce highly improved ...
(Date:7/23/2014)... -- regulated information -- UCB today announced an important ... positive topline results from the latest Phase 3 ... to evaluate the efficacy and safety of ... compared to placebo, as adjunctive treatment in adult ... controlled despite treatment with one or two concomitant ...
(Date:7/23/2014)... July 23, 2014  Sofinnova Ventures, a ... the closing of Sofinnova Venture Partners IX, L.P. at ... of the initial fund target of $425 million. ... biotechnology companies. Consistent with recent funds, SVP IX will ... clinical programs, along with select investments in earlier stage ...
Breaking Biology Technology:MSC and Cape Regional Medical Center Partner to Improve Cost, Quality and Outcomes 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 2Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 3Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 4Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 5Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 6Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures 7Sofinnova Raises $500 Million Biotech Venture Fund 2
... Its Kind Instant Dissolve Powder Antacid Delivers Faster Relief, ... Increased Convenience and Great Taste, ... a $20 million integrated marketing campaign,for the new TUMS(R) QuikPak(TM), ... TUMS brand. The QuikPak campaign, part of,a larger new "Bring ...
... Follow, FREDERICK, Md., April 21 ... for ActiPatch(TM) for,kidney-compromised patients. BioElectronics Corporation, (Pink ... revolutionary drug-free,anti-inflammatory patch which accelerates healing., ... ibuprofen,(Advil, Motrin, Nuprin) and Naproxen (Aleve, Anaprox, ...
... DUBLIN, Calif., April 21 SuperGen Inc.,(Nasdaq: ... discovery, rapid,development and commercialization of therapies for solid ... release its 2008,first quarter financial results on Monday, ... of the Company,s financial results and,any revised outlook ...
Cached Biology Technology:New TUMS(R) QuikPak(TM) Campaign Offers Innovative Heartburn Relief with a Little Help from the Jetsons 2Maryland Approves Medicaid Reimbursement for ActiPatch(R) 2SuperGen to Announce 2008 First Quarter Financial Results April 28, 2008 2
(Date:7/23/2014)... fur seals, alongside decades of in-depth monitoring, has ... change on a population of top-predators. Published in ... that the seals have significantly altered in accordance ... with climate conditions. Despite a shift in the ... passing down through generations, leaving the population in ...
(Date:7/23/2014)... issued a high health risk warning for Yellowknife and ... due to forest fires. In the image taken ... along normal wind patterns. Fire is an obvious ... is not quite so obvious and its effects are ... fire (forest, brush, crop, structure, tires, waste or wood ...
(Date:7/23/2014)... people around the world have no access to clean ... 3.4 million people die from water-related diseases every year. ... making a contribution to solving this problem. Working with ... of the Functional Materials Laboratory, the 23-year-old spent a ... , "What makes our DrinkPure filter unique is that ...
Breaking Biology News(10 mins):Genetic study shows major impact of climate change on Antarctic fur seals 2Genetic study shows major impact of climate change on Antarctic fur seals 3ETH student develops filter for clean water around the world 2
... leaf has revealed the oldest known evidence of a macabre ... to turn them into zombies. The discovery has been ... Hughes, from the University of Exeter, who studies parasites that ... manner of animals are susceptible to the often deadly body ...
... from Mount Sinai School of Medicine have enhanced our ... conversion, the process in which food is converted into ... scientists gain atomic-level insight into how organisms synthesize their ... published in the August issue of PLoS Biology ...
... Mont. -- Researchers at Montana State University have ... for treating antibiotic resistant infections, fungal infections and viral ... to study such compounds. The technologies are ... The first technology involves an existing clinical drug ...
Cached Biology News:Fossil reveals 48-million-year history of zombie ants 2Mount Sinai researchers discover new mechanism behind cellular energy conversion 2Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
... degradation is critical to the maintenance ... regulatory proteins as important and diverse ... heat shock and stress response, antigen ... and ion channels, cell cycle regulation, ...
... digital scanner serves as the spot-picking platform. ... standard rack positions on the tray, leaving ... plates on the remaining two racks.,The software ... by mouse-click on the scanned gel image. ...
...
Biology Products: